Lysosomal β-Galactosidase and β-Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Multiple epidemiological studies have shown that individuals affected by type-2 diabetes mellitus (T2DM) carry a 2-to-5-fold higher risk of developing Alzheimer's disease (AD) when compared to non-diabetic subjects. Thus, biochemical parameters that can be easily and routinely assessed for high-confidence evaluation of diabetic conditions leading to AD (AD-T2DM) are regarded as efficient tools aimed at early diagnosis and, in turn, timely AD treatment. In this regard, the activity of lysosomal glycohydrolases may of use, in light of the implication of these enzymes in early events that underlie AD pathology and an overt correlation, in diabetes, between altered metabolic homeostasis, abnormal glycohydrolase secretion in body fluids, and occurrence of diabetic complications. Based on marked up-regulation previously shown in a peripheral, cell-based model of AD, we selected β-Galactosidase, β-Hexosaminidase, and α-Mannosidase to discriminate T2DM from AD-T2DM subjects. A screen of 109, 114, and 116 patients with T2DM, AD and AD-T2DM, respectively, was performed by testing enzyme activities in both blood plasma and peripheral blood mononuclear cells. Compared to age-matched, healthy controls (n = 122), β-Galactosidase and β-Hexosaminidase activities markedly diverged across the three groups, whereas virtually unchanged values were observed for α-Mannosidase. In particular, plasma β-Galactosidase and β-Hexosaminidase levels were higher in patients with AD-T2DM compared to those w…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased level of SA-β-Gal was also found in plasma samples from AD patients, compared to controls [184,185].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [185]
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine
Zweig, M. H., & Campbell, G. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.561 · Cited by 6,569
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“Increased level of SA-β-Gal was also found in plasma samples from AD patients, compared to controls [184,185].”
ResultCellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
“Increased levels of senescent cells with higher SA-β-gal and p53 levels are also found and in plasma samples from AD patients and mouse models of AD (de la Monte et al., 1997; Tiribuzi et al., 2011; Magini et al., 2015; Caldeira et al., 2017).”
BackgroundTiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162
Self-citationEndo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?
Whyte, L. S., Lau, A. A., Hemsley, K. M., Hopwood, J. J., & Sargeant, T. J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13935 · Cited by 150
“Conversely, the activity of these enzymes, as well as that of a-mannosidase, within peripheral blood mononuclear cells is decreased, indicating that there may be greater secretion of these lysosomal enzymes into the extracellular milieu (Tiribuzi et al. 2011).”
BackgroundAre there roles for brain cell senescence in aging and neurodegenerative disorders?
Tan, F. C. C., Hutchison, E. R., Eitan, E., & Mattson, M. P. (2014) · Biogerontology · doi:10.1007/s10522-014-9532-1 · Cited by 116
Are the neuroprotective effects of exercise training systemically mediated?
Tari, A. R., Norevik, C. S., Scrimgeour, N. R., Kobro-Flatmoen, A., Storm-Mathisen, J., Bergersen, L. H., Wrann, C. D., Selbæk, G., Kivipelto, M., Moreira, J. B. N., et al. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.02.003 · Cited by 115
Teong, X., Liu, K., Vincent, A., Bensalem, J., Liu, B., Hattersley, K., Zhao, L.-J., Feinle-Bisset, C., Sargeant, T., Wittert, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02287-7 · Cited by 113
Autophagy Modulation as a Treatment of Amyloid Diseases
Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T. J., Martins, R., & Bharadwaj, P. (2019) · Molecules · doi:10.3390/molecules24183372 · Cited by 65
Trans-crocetin improves amyloid-β degradation in monocytes from Alzheimer's Disease patients.
Tiribuzi, R., Crispoltoni, L., Chiurchiù, V., Casella, A., Montecchiani, C., Pino, A. D. D., Maccarrone, M., Palmerini, C., Caltagirone, C., Kawarai, T., et al. (2017) · Journal of Neurological Sciences · doi:10.1016/j.jns.2016.11.004 · Cited by 62
Self-citationMorena, F., Argentati, C., Trotta, R., Crispoltoni, L., Stabile, A., Pistilli, A., Di Baldassarre, A., Calafiore, R., Montanucci, P., Basta, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081806 · Cited by 57
“Other indirect links between lysosomal aberrations and neurodegeneration came from data reporting the involvement of proteases in the proteolysis of Aβ-peptide [24,25] or showing the abnormal levels of Hexosaminidase and Galactosidases in cells from severe AD patients [22,26,27,30,31].”
BackgroundMethodInfluentialSelf-citationTortorella, I., Argentati, C., Emiliani, C., Morena, F., & Martino, S. (2022) · Cells · doi:10.3390/cells11193093 · Cited by 41
Self-citationMolecular Mechanisms of Cellular Senescence in Neurodegenerative Diseases
Lee, H.-J., Yoon, Y.-S., & Lee, S.-J. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168114 · Cited by 36
Yamada, C., Akkaoui, J., Ho, A., Duarte, C., Deth, R., Kawai, T., Nichols, F., Lakshmana, M., & Movila, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591571 · Cited by 32
The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain
Sims-Robinson, C., Bakeman, A., Rosko, A., Glasser, R., & Feldman, E. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9207-1 · Cited by 31
Spazzafumo, L., Mensà, E., Matacchione, G., Galeazzi, T., Zampini, L., Recchioni, R., Marcheselli, F., Prattichizzo, F., Testa, R., Antonicelli, R., et al. (2017) · OncoTarget · doi:10.18632/oncotarget.21848 · Cited by 28
“This hypothesis is reinforced by the evidence that lysosomal dysfunctions are associated with the onset and progression of many age-related diseases (ARDs), including Parkinson’s and Alzheimer’s disease (AD) [4, 5] and type 2 diabetes (T2DM) [6, 7].”
BackgroundResultInfluentialMolecules of senescent glial cells differentiate Alzheimer’s disease from ageing
Dai, L., Gao, F., Wang, Q., Lv, X.-Y., Cheng, Z.-Z., Wu, Y., Chai, X., Zetterberg, H., Blennow, K., Levey, A., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330743 · Cited by 26
Purkinje Cell Loss in Essential Tremor
Chiasserini, D., Persichetti, E., Paciotti, S., Beccari, T., & Parnetti, L. (2014) · Movement Disorders · doi:10.1002/mds.25965 · Cited by 26
Schwann cell p75 neurotrophin receptor modulates small fiber degeneration in diabetic neuropathy
Gonçalves, N., Jager, S. E., Richner, M., Murray, S., Mohseni, S., Jensen, T., & Vægter, C. (2020) · Glia · doi:10.1002/glia.23881 · Cited by 24
“Lysosomal dysfunction has been reported in diabetes, aging and age-related degenerative diseases (Mattson & Arumugam, 2018; Pasquier et al., 2019; Rivera et al., 2010; Tiribuzi et al., 2011).”
BackgroundCrispoltoni, L., Stabile, A., Pistilli, A., Venturelli, M., Cerulli, G., Fonte, C., Smania, N., Schena, F., & Rende, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160625 · Cited by 22
Self-citationNitric oxide depletion alters hematopoietic stem cell commitment toward immunogenic dendritic cells.
Tiribuzi, R., Crispoltoni, L., Tartacca, F., Orlacchio, A., Martino, S., Palmerini, C., & Orlacchio, A. (2013) · Biochimica et Biophysica Acta · doi:10.1016/j.bbagen.2012.10.019 · Cited by 22
Self-citationWittkowski, K. M., Dadurian, C., Seybold, M. P., Kim, H. S., Hoshino, A., & Lyden, D. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199012 · Cited by 22
Lysosomal Dysregulation in the Murine App Model of Alzheimer’s Disease
Whyte, L. S., Hassiotis, S., Hattersley, K. J., Hemsley, K. M., Hopwood, J. J., Lau, A. A., & Sargeant, T. J. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.042 · Cited by 22
Functionalized Silica Star-Shaped Nanoparticles and Human Mesenchymal Stem Cells: An In Vitro Model
Argentati, C., Morena, F., Fontana, C., Tortorella, I., Emiliani, C., Latterini, L., Zampini, G., & Martino, S. (2021) · Nanomaterials · doi:10.3390/nano11030779 · Cited by 15
“Cell lysis was carried out as described in our previous works [56–58].”
Self-citationZhu, H., & Slonim, D. (2024) · bioRxiv · doi:10.1089/cmb.2024.0607 · Cited by 12
“(While we didn’t find prior evidence explicitly showing ApoE regulating β -hexosaminidase ( Hexa , Hexb ), there is evidence that they are both implicated in, and have correlated expression in, AD pathology [55,49], suggesting such a relationship is plausible).”
BackgroundLuo, L., Que, M., Zeng, L., Wang, X., Sun, T., Zhou, Z., Zhao, Y., Li, S., & Luo, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107947 · Cited by 13
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 11
“Studies conducted in our laboratory led to the observation that alterations in lysosomal glycohydrolases (Gal, Hex, β-Galactosylcerebrosidase, CatB and Cathepsin S (CatS)) were detectable also in peripheral districts such as blood plasma and the Peripheral Blood Mononuclear Cells (PBMCs) of AD patients, and that some…”
BackgroundSelf-citationBicchi, I., Emiliani, C., Vescovi, A., & Martino, S. (2015) · Neurodegenerative Diseases · doi:10.1159/000435917 · Cited by 9
Self-citationMoayedi, K., Orandi, S., Ebrahimi, R., Tanhapour, M., Moradi, M., Abbastabar, M., & Golestani, A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30779 · Cited by 13
Bicchi, I., Morena, F., Argentati, C., Nodari, L. R., Emiliani, C., Gelati, M., Vescovi, A. L., & Martino, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091080 · Cited by 8
“Enzyme activities were measured using fluorometric commercially available substrates as described in our previous works [34,35,38,39].”
MethodResultSelf-citationTarquini, F., Tiribuzi, R., Crispoltoni, L., Porcellati, S., Pino, A. D. D., Orlacchio, A., Coata, G., Arnone, S., Torlone, E., Cappuccini, B., et al. (2014) · Cell Biochemistry and Function · doi:10.1002/cbf.2975 · Cited by 8
Self-citationChiu, S., Khan, A., Badmaev, V., Terpstra, K. J., Cernovsky, Z., Varghese, J., Khazaeipool, Z., Elias, H., Carriere, A., Husni, M., et al. (2017) · Journal of Systems and Integrative Neuroscience · doi:10.15761/jsin.1000158 · Cited by 3
“A recent study found evidence for upregulation of lysosomal enzymes [32].”
BackgroundGolpasandi, H., & Rahimi, M. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/8817195 · Cited by 2
“However, lysosomal disorders, which disrupt the degradation capacity of lysosomes, also play a role in the pathology of T2DM [6].”
Carassius auratus as a novel model for the hyperglycemia study
Falfushynska, H., Horyn, O., & Gnatyshyna, L. (2019) · Ukrainian Biochemical Journal · doi:10.15407/ubj91.04.058 · Cited by 1
“Also the expression of aspartyl lysosomal protease namely cathepsin D increased in serum and leucocytes of type 2 diabetes patients [39] and in both the cortex and hippocampus in T2D db/db mice [41].”
BackgroundWittkowski, K., Dadurian, C., Seybold, M. P., Kim, H., Hoshino, A., & Lyden, D. (2017) · bioRxiv · doi:10.1101/152405 · Cited by 1
Wittkowski, K., Dadurian, C., Seybold, M. P., Kim, H., Hoshino, A., & Lyden, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214826 · Cited by 1
Linking Enzyme Upregulation to Autophagic Failure: A Potential Biomarker for GM1 GangliosidosisPreprint
Smith, S. E., & Larsen, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.28.359083 · Cited by 1
Metadata
- Authors
- Tiribuzi, R., Orlacchio, A., Crispoltoni, L., Maiotti, M., Zampolini, M., De Angeliz, M., Mecocci, P., Cecchetti, R., Bernardi, G., Datti, A., Martino, S., & Orlacchio, A.
- Affiliations
- University of Perugia (IT)
- University of Rome Tor Vergata (IT)
- Neuropsicologia Clinica, Ospedale S. Giovanni Battista, Foligno, Italy
- U.O. S.S. Ambulatoriale di Diabetologia Di.M.I., University of Perugia, Perugia, Italy
- Corresponding author
- Orlacchio, Aldo
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-05-30
- Volume
- 24
- Issue
- 4
- Pages
- 785-797
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1772878786
- Cited by
- 43
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, type 2 diabetes
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, beta-Galactosidase, beta-N-Acetylhexosaminidases, Dementia, Diabetes Mellitus, Type 2, Enzyme Activation, Female, Humans, Lysosomes, Male, Biomarkers, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.